Table 3 Patient withdrawal due to adverse events: first course of anti-TNF therapy
Adverse event leading to withdrawal (MedDRA system organ classification) | Etanercept (n = 316) | Infliximab (n = 162) | Adalimumab (n = 88) |
|---|---|---|---|
Immune system disordersa | 2 (0.6) | 12 (7.4) | 1 (1.1) |
General disorders and administration site conditionsb | 2 (0.6) | 2 (1.2) | 0 (0.0) |
Infections and infestations | 15 (4.7) | 3 (1.9) | 3 (3.4) |
Gastrointestinal disorders | 4 (1.3) | 4 (2.5) | 1 (1.1) |
Hepatobiliary disorders | 1 (0.3) | 2 (1.2) | 0 (0.0) |
Respiratory, thoracic and mediastinal disorders | 1 (0.3) | 0 (0.0) | 0 (0.0) |
Renal and urinary disorders | 1 (0.3) | 1 (0.6) | 0 (0.0) |
Cardiac disorders | 1 (0.3) | 3 (1.9) | 0 (0.0) |
Blood and lymphatic system disorders | 2 (0.6) | 1 (0.6) | 2 (2.3) |
Nervous system disorders | 3 (0.9) | 5 (3.1) | 1 (1.1) |
Skin and subcutaneous tissue disorders | 3 (0.9) | 3 (1.9) | 3 (3.4) |
Metabolism and nutrition disorders | 0 (0.0) | 0 (0.0) | 1 (1.1) |
Psychiatric disorders | 1 (0.3) | 0 (0.0) | 0 (0.0) |
Neoplasms benign, malignant and unspecified (including cysts and polyps) | 3 (0.9) | 2 (1.2) | 1 (1.1) |
Total | 39 (12.3) | 38 (23.5) | 13 (14.8) |